Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Rubber granulate on synthetic turf fields causes environmental impact Use of rubber granulate sourced from car tyres, on synthetic turf fields can be harmful to the environment in the close vicinity of these fields.
One Health European Joint Programme (EJP) Expert Meeting On the 4th and 5th of June 2018, an expert meeting was held at RIVM to redefine and prioritise the topics for One Health research and integrative activities in Europe.
People who eat meat do not carry more ESBL bacteria RIVM research reveals that people who eat meat regularly do not carry ESBLs more frequently than vegetarians.
PhD dissertation: Dutch Q fever epidemic in 'One Health' context Today Barbara Schimmer will be defending her PhD dissertation entitled The Q fever epidemic in the Netherlands in a One Health context, at Utrecht University.
Lyme disease cases have quadrupled According to a survey by RIVM , 27,000 people were infected with Lyme disease in 2017. In 2014, the last time RIVM reported on the incidence of tick-borne disease, this number was 25,000.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.